Johnson & Johnson Unveils New Pulsed Field Ablation Data for Atrial Fibrillation at APHRS and JPHRS
Reuters
Nov 03
Johnson & Johnson Unveils New Pulsed Field Ablation Data for Atrial Fibrillation at APHRS and JPHRS
Johnson & Johnson has announced the latest advancements in Pulsed Field Ablation technology, highlighting multiple clinical and real-world studies to be presented at the Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JPHRS) meetings. Key presentations include new data on safety, efficacy, and workflow improvements intended to optimize irrigation and support consistent procedural outcomes in atrial fibrillation care. Specific sessions will address topics such as bilateral first pass isolation, the benefits of carina ablation in addition to pulmonary vein isolation, and sex differences in left atrial scar burden and ablation outcomes. Additionally, results from the QUEST AF study on the acute success of persistent atrial fibrillation ablation using a temperature-controlled, very high-power short-duration radiofrequency catheter will be presented. Johnson & Johnson MedTech continues to collaborate with the clinical community to expand real-world evidence around its VARIPULSE™ Platform and advance innovation in atrial fibrillation treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.